×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
BIO – bio-rad laboratories, inc. class a (US:NYSE)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
BIO
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
3/4
07:25 am
bio
Digital PCR Market Size to Hit USD 35.32 Billion by 2035, Fueled by Rising Cancer Prevalence and Precision Oncology Demand – SNS Insider [Yahoo! Finance]
Low
Report
Digital PCR Market Size to Hit USD 35.32 Billion by 2035, Fueled by Rising Cancer Prevalence and Precision Oncology Demand – SNS Insider [Yahoo! Finance]
2/19
02:47 pm
bio
Bio-Rad Laboratories, Inc. (BIO) Achieves Modest Revenue Growth and Robust Free Cash Flow Growth [Yahoo! Finance]
Low
Report
Bio-Rad Laboratories, Inc. (BIO) Achieves Modest Revenue Growth and Robust Free Cash Flow Growth [Yahoo! Finance]
2/12
04:15 pm
bio
Bio-Rad Reports Fourth-Quarter and Full-Year 2025 Financial Results
High
Report
Bio-Rad Reports Fourth-Quarter and Full-Year 2025 Financial Results
1/29
08:30 am
bio
Bio-Rad to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 12, 2026
Low
Report
Bio-Rad to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 12, 2026
1/7
11:04 pm
bio
???????????????????????????2035????834?8000????????????????? [CNET News]
Low
Report
???????????????????????????2035????834?8000????????????????? [CNET News]
1/6
08:45 am
bio
Bio-Rad’s Management to Host Investor Meetings at J.P. Morgan's 44th Annual Healthcare Conference
Low
Report
Bio-Rad’s Management to Host Investor Meetings at J.P. Morgan's 44th Annual Healthcare Conference
Date
Time
Symbol
Company Name
Action
%Chg
2/12/2026
04:15 pm
BIO
bio-rad laboratories, inc. class a
MISS
Report
-12.3%
bio-rad laboratories, inc. class a
10/29/2025
04:15 pm
BIO
bio-rad laboratories, inc. class a
MISS
Report
-6.5%
bio-rad laboratories, inc. class a
7/31/2025
04:15 pm
BIO
bio-rad laboratories, inc. class a
BEAT
Report
17.6%
bio-rad laboratories, inc. class a
5/1/2025
04:15 pm
BIO
bio-rad laboratories, inc. class a
BEAT
Report
-1.7%
bio-rad laboratories, inc. class a
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
2/19
04:16 pm
bio
Form 8-K BIO-RAD LABORATORIES, For: Feb 19
Low
Report
Form 8-K BIO-RAD LABORATORIES, For: Feb 19
2/13
06:06 am
bio
Form 10-K BIO-RAD LABORATORIES, For: Dec 31
Low
Report
Form 10-K BIO-RAD LABORATORIES, For: Dec 31
2/12
04:16 pm
bio
Form 8-K BIO-RAD LABORATORIES, For: Feb 12
High
Report
Form 8-K BIO-RAD LABORATORIES, For: Feb 12
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
4/8
Biodesix Begins Coronavirus COVID-19 Testing
8.8%
3/12 Bio-Rad Announces that Through its Exact Diagnostics Product Line, the Company has Launched a SARS CoV-2 Standard for Coronavirus (COVID-19) Testing 8.7%
8/1 Form 8-K BIO-RAD LABORATORIES, For: Aug 01 8.3%
4/1 Form 3 BIO-RAD LABORATORIES, For: Apr 01 Filed by: RAMALINGAM AJIT 7.7%
2/13 Bio-Rad Reports Fourth-Quarter and Full-Year 2019 Financial Results 7.4%
10/31 Q3/2019 9/30/2019 EPS 1.610 ZacksConsensus 1.360 ActVsEst 0.250 - Beat 6.2%
5/8 Q1/2019 3/31/2019 EPS 1.650 ZacksConsensus 1.120 ActVsEst 0.530 - Beat 4.3%
3/2 Form 10-K BIO-RAD LABORATORIES, For: Dec 31 4.1%
12/13 Bio-Rad Makes Progress Recovering from Recent Ransomware Attack 3.5%
3/30 Bio-Rad Laboratories, Inc. (NYSE: BIO) had its price target lowered by analysts at Wells Fargo & Co from $440.00 to $385.00. They now have an "overweight" rating on the stock. 3.4%
3/12 Bio-Rad Announces that Through its Exact Diagnostics Product Line, the Company has Launched a SARS CoV-2 Standard for Coronavirus (COVID-19) Testing 8.7%
8/1 Form 8-K BIO-RAD LABORATORIES, For: Aug 01 8.3%
4/1 Form 3 BIO-RAD LABORATORIES, For: Apr 01 Filed by: RAMALINGAM AJIT 7.7%
2/13 Bio-Rad Reports Fourth-Quarter and Full-Year 2019 Financial Results 7.4%
10/31 Q3/2019 9/30/2019 EPS 1.610 ZacksConsensus 1.360 ActVsEst 0.250 - Beat 6.2%
5/8 Q1/2019 3/31/2019 EPS 1.650 ZacksConsensus 1.120 ActVsEst 0.530 - Beat 4.3%
3/2 Form 10-K BIO-RAD LABORATORIES, For: Dec 31 4.1%
12/13 Bio-Rad Makes Progress Recovering from Recent Ransomware Attack 3.5%
3/30 Bio-Rad Laboratories, Inc. (NYSE: BIO) had its price target lowered by analysts at Wells Fargo & Co from $440.00 to $385.00. They now have an "overweight" rating on the stock. 3.4%
TOP News Decliners
3/20
Biodesix Partners with Bio-Rad to Bring Emergency Use Authorization (EUA) COVID-19 ddPCR™ Test to the U.S.
-5.5%
8/2 Bio-Rad Laboratories, Inc. (NYSE: BIO) was upgraded by analysts at ValuEngine from a "hold" rating to a "buy" rating. -5.1%
5/10 Form 10-Q BIO-RAD LABORATORIES, For: Mar 31 -4.8%
12/9 Form 8-K BIO-RAD LABORATORIES, For: Dec 05 -4.4%
9/9 Form 4 BIO-RAD LABORATORIES, For: Sep 05 Filed by: TUMOLO ANNETTE -3.7%
3/18 Bio-Rad Partners with Testing Labs Worldwide to Support COVID-19 Testing -3.4%
4/6 Form 8-K BIO-RAD LABORATORIES, For: Apr 01 -2.9%
4/9 Bio-Rad Acquires Celsee, Inc., a Single-Cell Analysis Solutions Provider -2.4%
4/21 Bio-Rad Begins Shipping SARS-COV-2 (COVID-19) Antibody Test That Offers More Than 99 Percent Specificity and 98 Percent Sensitivity -1.7%
9/20 Bio-Rad Laboratories, Inc. (NYSE: BIO) was upgraded by analysts at ValuEngine from a "hold" rating to a "buy" rating. -1.6%
8/2 Bio-Rad Laboratories, Inc. (NYSE: BIO) was upgraded by analysts at ValuEngine from a "hold" rating to a "buy" rating. -5.1%
5/10 Form 10-Q BIO-RAD LABORATORIES, For: Mar 31 -4.8%
12/9 Form 8-K BIO-RAD LABORATORIES, For: Dec 05 -4.4%
9/9 Form 4 BIO-RAD LABORATORIES, For: Sep 05 Filed by: TUMOLO ANNETTE -3.7%
3/18 Bio-Rad Partners with Testing Labs Worldwide to Support COVID-19 Testing -3.4%
4/6 Form 8-K BIO-RAD LABORATORIES, For: Apr 01 -2.9%
4/9 Bio-Rad Acquires Celsee, Inc., a Single-Cell Analysis Solutions Provider -2.4%
4/21 Bio-Rad Begins Shipping SARS-COV-2 (COVID-19) Antibody Test That Offers More Than 99 Percent Specificity and 98 Percent Sensitivity -1.7%
9/20 Bio-Rad Laboratories, Inc. (NYSE: BIO) was upgraded by analysts at ValuEngine from a "hold" rating to a "buy" rating. -1.6%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: